Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00KIE
|
|||
Former ID |
DIB015508
|
|||
Drug Name |
Ensaculin hydrochloride
|
|||
Synonyms |
Anseculin hydrochloride; Ensaculin hydrochloride; KA-672.HCl; 7-Methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethyl-2H-1-benzopyran-2-one hydrochloride
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 2 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C26H33ClN2O5
|
|||
Canonical SMILES |
CC1=C(C(=O)OC2=CC(=C(C=C12)OCCCN3CCN(CC3)C4=CC=CC=C4OC)OC)C.Cl
|
|||
InChI |
1S/C26H32N2O5.ClH/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3;/h5-6,8-9,16-17H,7,10-15H2,1-4H3;1H
|
|||
InChIKey |
XMONKHCPLIYQCY-UHFFFAOYSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Modulator | [1], [2] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Serotonergic synapse | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
5HT1 type receptor mediated signaling pathway | ||||
Reactome | Serotonin receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
SIDS Susceptibility Pathways | ||||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58. | |||
REF 2 | The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component. Pharmacol Biochem Behav. 1998 Jul;60(3):703-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.